Trial Profile
A Pilot Study Comparing Olanzapine and Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Receiving Highly Emetogenic Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Olanzapine (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 09 Mar 2017 Status changed from recruiting to completed.
- 25 Jun 2014 New trial record